We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

Back to rankings

212 hedge funds and large institutions have $2.12B invested in Portola Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 92 increasing their positions, 46 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 46

42% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 26

10% more capital invested

Capital invested by funds: $1.92B → $2.12B (+$201M)

5% more funds holding

Funds holding: 202 → 212 (+10)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

51% less call options, than puts

Call options by funds: $9.14M | Put options by funds: $18.6M

Holders
212
Holders Change
+10
Holders Change %
+4.95%
% of All Funds
4.65%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.13%
New
37
Increased
92
Reduced
46
Closed
26
Calls
$9.14M
Puts
$18.6M
Net Calls
-$9.46M
Net Calls Change
-$2.74M

Top Buyers

Rank Fund Capital Flow
1
William Blair Investment Management
William Blair Investment Management
Illinois
+$52.3M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$34.1M
3
BlackRock
BlackRock
New York
+$25.1M
4
FLAM
First Light Asset Management
Minnesota
+$21.4M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$20.5M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$17.4M
2
CCM
Cadian Capital Management
New York
-$11.9M
3
State Street
State Street
Massachusetts
-$11.8M
4
ACM
Asymmetry Capital Management
California
-$10.5M
5
Morgan Stanley
Morgan Stanley
New York
-$7.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
Neuberger Berman Group
76
Neuberger Berman Group
New York
$2.95M -$502K -17,900 -14%
Royal Bank of Canada
77
Royal Bank of Canada
Ontario, Canada
$2.9M +$514K +18,308 +20%
EVM
78
Eaton Vance Management
Massachusetts
$2.87M +$3M +106,920 New
ELI
79
Empire Life Investments
Ontario, Canada
$2.82M +$1.29M +46,053 +78%
WCM
80
Wisconsin Capital Management
Wisconsin
$2.72M +$421K +15,000 +17%
JG
81
Jefferies Group
New York
$2.72M -$3.15M -112,133 -53%
RhumbLine Advisers
82
RhumbLine Advisers
Massachusetts
$2.65M +$180K +6,426 +7%
AllianceBernstein
83
AllianceBernstein
Tennessee
$2.56M +$50.5K +1,800 +2%
ACM
84
Atika Capital Management
New York
$2.52M -$168K -6,000 -6%
Fisher Asset Management
85
Fisher Asset Management
Washington
$2.39M -$327K -11,655 -12%
State of New Jersey Common Pension Fund D
86
State of New Jersey Common Pension Fund D
New Jersey
$2.37M +$2.48M +88,200 New
Tudor Investment Corp
87
Tudor Investment Corp
Connecticut
$2.22M +$535K +19,043 +30%
GAM
88
Gotham Asset Management
New York
$2.13M +$2.23M +79,303 New
UBS AM
89
UBS AM
Illinois
$1.92M +$543K +19,343 +37%
Victory Capital Management
90
Victory Capital Management
Texas
$1.91M +$1.95M +69,547 +4,519%
PPA
91
Parametric Portfolio Associates
Washington
$1.86M -$238K -8,487 -11%
WP
92
WealthPLAN Partners
Nebraska
$1.83M +$59.6K +2,123 +3%
GC
93
Guggenheim Capital
Illinois
$1.77M -$142K -5,056 -7%
MSL
94
Mackay Shields LLC
New York
$1.61M -$42.1K -1,500 -2%
Envestnet Asset Management
95
Envestnet Asset Management
Illinois
$1.6M +$437K +15,576 +35%
SI
96
Sofinnova Investments
California
$1.59M +$1.66M +59,191 New
AQR Capital Management
97
AQR Capital Management
Connecticut
$1.58M +$72.1K +2,567 +5%
T. Rowe Price Associates
98
T. Rowe Price Associates
Maryland
$1.41M -$258K -9,195 -15%
JP Morgan Chase
99
JP Morgan Chase
New York
$1.3M -$17.4M -619,731 -93%
AIG
100
American International Group
New York
$1.27M +$133K +4,755 +11%
2 3
4
5 6

PTLA Hedge Fund Activity: Q3 2019 in Review

212 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q3 2019, worth a combined $2.12B — up 10% from $1.92B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new PTLA positions and 26 closed out — a net gain of 11 holders — while 92 added to existing stakes and 46 trimmed.

The largest buyer was William Blair Investment Management, adding an estimated $52.3M. The largest seller was JP Morgan Chase, cutting an estimated $17.4M.

  • 212 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q3 2019, up from 202 in Q2 2019.
  • Funds reported $2.12B of Portola Pharmaceuticals, Inc. stock for Q3 2019, up 10% quarter-over-quarter.
  • 37 funds opened new Portola Pharmaceuticals, Inc. positions in Q3 2019 and 26 closed out, a net change of +11 holders.
  • The largest Portola Pharmaceuticals, Inc. buyer in Q3 2019 was William Blair Investment Management, an estimated $52.3M added.
  • The largest Portola Pharmaceuticals, Inc. seller in Q3 2019 was JP Morgan Chase, an estimated $17.4M sold.

Based on aggregated 13F filings for Q3 2019.